Several Johnson & Johnson drugs are contributing strong growth, but some struggling medicines weighed on the company’s overall performance. More: Earnings bulletin: Johnson & Johnson's second quarter of 2019 Source: fierce
read moreCalled a “kingpin” and accused of launching a “multibillion brainwashing campaign” to sell its opioid drugs, Johnson & Johnson has run the gantlet in its court battle with the state of Oklahoma. But name-calling aside, should J&J be held responsible
read moreJohnson & Johnson’s pharma unit is still churning out growth, partly because of outperforming new launches like cancer med Darzalex. But execs had to explain away some disappointing results for blockbusters Zytiga and Xarelto. More: J&J execs have plenty to
read moreNovartis’ plan to launch over 10 potential blockbuster drugs or new indications by 2021 is quickly unfolding. The FDA has accepted a biologics application for the pharma giant’s sickle cell disease candidate crizanlizumab. More: Novartis’ crizanlizumab wins speedy FDA review, putting
read moreAs the 2020 election revs up, candidates are again targeting drug prices, with tough action plans from two Democratic candidates in just two days. And brace yourselves, drugmakers: Even rougher campaign waters are ahead, analysts figure. More: Who's toughest on
read moreA new ‘transfer window’ lets staff move within the NHS between areas while developing new skills. More: NHS rolls out staff retention scheme Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals